Finally, as the same mutations for PTPN11 are found in disseminated human HS27, the identification and kinetic quantification of such driver mutations in the plasma are key to proposing and evaluating new targeted therapies in canine models for rare and aggressive human cancer, with benefits for both veterinary and human medicine. The gene discussed is PTPN11; the disease is cancer.